Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.

Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H

Calcified tissue international16 Oct 2010Cited by 82 (Europe PMC)

PMID20953593PMCIDPMC2978887DOI10.1007/s00223-010-9424-6PepBankPUB-20953593

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialPharmacokinetics
In postmenopausal women with osteoporosis, teriparatide reached maximum concentration within 30 min.
In plain wordsIn women with osteoporosis, teriparatide reached its highest concentration within 30 min.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTime to maximum concentration
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Time to maximum concentration
≤ 30 min
Teriparatide 20 μg, subcutaneous
Source sentences
Summary
The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half-life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359301
02HumanNon-randomized trialPharmacokinetics
In postmenopausal women with osteoporosis, teriparatide had a half-life of 1 h.
In plain wordsIn women with osteoporosis, teriparatide had a half-life of 1 h.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableElimination half-life
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Elimination half-life
1 h
Teriparatide 20 μg, subcutaneous
Source sentences
Summary
The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half-life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359302
03HumanNon-randomized trialPharmacokinetics
In postmenopausal women with osteoporosis, teriparatide exposure lasted approximately 4 h.
In plain wordsIn women with osteoporosis, teriparatide exposure lasted approximately 4 h.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableDuration of peptide exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Total duration of exposure to teriparatide
≈ 4 h
Teriparatide 20 μg, subcutaneous
Source sentences
Summary
The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half-life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359303
04HumanNon-randomized trialActivity measurement
In women with osteoporosis, teriparatide transiently increased serum calcium, with a median increase of 0.4 mg/dl at approximately 4.25 h.
In plain wordsIn women with osteoporosis, teriparatide temporarily increased blood calcium compared with predose levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeak serum calcium response
Study
n: not reported in source
Comparator
Predose
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Median increase in serum calcium at maximum effect
0.4 mg/dl
Teriparatide 20 μg, after dose
Time of maximum serum calcium effect
≈ 4.25 h
Teriparatide 20 μg, after dose
Source sentences
Summary
Teriparatide transiently increased serum calcium, with the maximum effect observed at approximately 4.25 h (median increase 0.4 mg/dl [0.1 mmol/l]).
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359304
05HumanNon-randomized trialActivity measurement
In women with osteoporosis, serum calcium returned to predose levels by 16-24 h after teriparatide.
In plain wordsIn women with osteoporosis, blood calcium returned to predose levels by 16-24 h after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerum calcium return to predose
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Time for serum calcium to return to predose levels
16 to 24 h
After each teriparatide dose
Source sentences
Summary
Calcium concentrations returned to predose levels by 16-24 h after each dose.
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359305
06HumanNon-randomized trialSafety outcome
In women with osteoporosis receiving teriparatide, persistent hypercalcemia was not observed.
In plain wordsIn women with osteoporosis receiving teriparatide, persistent high blood calcium was not observed.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePersistent hypercalcemia
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Source sentences
Summary
Persistent hypercalcemia was not observed; one teriparatide 20 μg-treated patient had a predose serum calcium value above the normal range but <11.0 mg/dl (2.75 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359306
07HumanNon-randomized trialSafety outcome
One teriparatide-treated woman had predose calcium above normal but below 11.0 mg/dl.
In plain wordsOne woman receiving teriparatide had blood calcium above normal before a dose, but below 11.0 mg/dl.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableElevated predose calcium
Study
n: not reported in source
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 μg daily · subcutaneous · median 21 monthsAs given in this study (human).
Measurements
Teriparatide-treated patients with predose serum calcium above normal range
1 patients
Teriparatide 20 μg group
Predose serum calcium in that patient
< 11 mg/dl
Teriparatide 20 μg group
Source sentences
Summary
Persistent hypercalcemia was not observed; one teriparatide 20 μg-treated patient had a predose serum calcium value above the normal range but <11.0 mg/dl (2.75 mmol/l).
2 context sentences(design, population, supporting numbers)
Summary · context
Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial.
Summary · context
Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 μg (4.86 μmol) or placebo, median 21 months' treatment.
Report a problemFND-2095359307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.